期刊文献+

质子泵抑制三联疗法联合荆花胃康治疗Hp相关慢性消化性溃疡的疗效观察 被引量:3

Proton pump inhibitor triple therapy combined with Jinghua Weikang in treatment of Hp related chronic peptic ulcer
下载PDF
导出
摘要 目的探讨质子泵抑制三联疗法联合荆花胃康治疗对幽门螺杆菌(Hp)相关慢性消化性溃疡的临床效果。方法选取2019年3月至2020年3月广州市越秀区中医医院收治且符合研究纳入条件的92例Hp相关慢性消化性溃疡患者,将其采用Excel表编码后以随机数字表法分为对照组与研究组,每组46例。对照组患者中,男性26例、女性20例,年龄(45.68±6.42)岁;研究组患者中,男性24例、女性22例,年龄(46.33±6.50)岁。对照组患者行常规质子泵抑制三联治疗,研究组患者则在质子泵抑制三联疗法基础上联合中成药荆花胃康胶丸治疗,观察两组临床疗效、中医症候积分变化、Hp清除率与血清学指标变化情况。结果研究组总有效率为93.48%(43/46),较对照组的76.09%(35/46)高(χ2=5.392,P<0.05)。研究组腹胀、嗳气、腹痛、纳差评分分别为(1.34±0.16)分、(1.28±0.14)分、(1.31±0.17)分及(1.20±0.11)分,依次低于对照组的(1.53±0.18)分、(1.48±0.16)分、(1.58±0.19)分及(1.37±0.13)分(t=3.944、4.703、5.295、4.991,均P<0.05)。研究组血清免疫球蛋白(Ig)A、IgG、IgM水平分别为(2.91±0.36)g/L、(11.02±2.20)g/L、(1.83±0.26)g/L,依次高于对照组的(2.38±0.31)g/L、(9.45±2.24)g/L、(1.41±0.24)g/L(t=5.578、2.500、5.935,均P<0.05)。研究组Hp根除率为86.96%(40/46),较对照组的69.57%(32/46)高(χ2=4.089,P<0.05)。结论质子泵抑制三联疗法联合荆花胃康治疗Hp相关慢性消化性溃疡,能够促进患者临床症状改善,同时有助于提高其机体免疫水平与Hp感染的根除效果,临床应用效果显著。 Objective To investigate the clinical effect of proton pump inhibitor triple therapy combined with Jinghua Weikang in the treatment of Helicobacter pylori(Hp)related chronic peptic ulcer.Methods Ninety-two patients with HP-related chronic peptic ulcer who were admitted to Yuexiu District Hospital of Traditional Chinese Medicine from March 2019 to March 2020 and qualified for the study's inclusion were selected.They were divided into a control group and a research group by a random number table encoded in Excel.The control group received conventional proton pump inhibitor triple therapy,and the research group proton pump inhibitor triple therapy and Jinghua Weikang capsules.The clinical efficacies,changes in TCM syndrome scores,Hp clearance rates,and changes in serological indicators of the two groups were observed and compared.Results The total effective rate was 93.48%(43/46)in the study group,and was 76.09%(35/46)in the control group(χ2=5.392,P<0.05).The scores of abdominal distension,belching,abdominal pain,and anorexia were(1.34±0.16),(1.28±0.14),(1.31±0.17),and(1.20±0.11)in the study group,and were(1.53±0.18),(1.48±0.16),(1.58±0.19),and(1.37±0.13)in the control group(t=3.944,4.703,5.295,and 4.991,all P<0.05).The levels of serum immunoglobulin(Ig)A,G,and M were(2.91±0.36)g/L,(11.02±2.20)g/L in the study group,and(1.83±0.26)g/L,and were(2.38±0.31)g/L,(9.45±2.24)g/L,(1.41±0.24)g/L in the control group(t=5.578,2.500,and 5.935,all P<0.05).The Hp eradication rate was 86.96%(40/46)in the study group,and was 69.57%(32/46)in the control group(χ2=4.089,P<0.05).Conclusion Proton pump inhibitor triple therapy combined with Jinghua Weikang in the treatment of Hp related chronic peptic ulcer can improve the patients'clinical symptoms and immune level and the eradication effect of Hp infection,with significant clinical application effect.
作者 岑永豪 Chen Yonghao(Department of Emergency Internal Medicine,Yuexiu District Hospital of Traditional Chinese Medicine,Guangzhou 510030,China)
出处 《国际医药卫生导报》 2021年第15期2359-2362,共4页 International Medicine and Health Guidance News
关键词 慢性消化性溃疡 HP感染 质子泵抑制剂 三联疗法 荆花胃康 Chronic peptic ulcer Hp infection Proton pump inhibitors Triple therapy Jinghua Weikang
  • 相关文献

参考文献15

二级参考文献201

共引文献410

同被引文献34

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部